Date: 2016-05-03
Type of information: R&D agreement
Compound: gene therapies
Company: Orchard Therapeutics (UK) University College London (UK) Great Ormond Street Hospital for Children NHS Foundation Trust (UK) the University of Manchester (UK) the University of California Los Angeles (USA - CA) Boston Children’s Hospital (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: R&D
Action mechanism: gene therapy
Disease:
Details: * On May 3, 2016, Orchard Therapeutics has announced partnerships with University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester, the University of California Los Angeles and Boston Children’s Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases. Orchard has chose a collaborative development model for its research programmes, working closely with clinicians and researchers at leading academic centres. Orchard’s Scientific Advisory Board is comprised of world-leading researchers in gene therapy and rare diseases, including Professor Alessandra Biffi (Dana Faber/Boston Children’s Hospital), Dr Brian Bigger (The University of Manchester), Professor Bobby Gaspar (UCL/GOSH), Dr Simon Jones (Central Manchester University Hospitals NHS Foundation Trust), Professor Donald Kohn (UCLA), Professor Fulvio Mavilio (Genethon), Professor Waseem Qasim and Professor Adrian Thrasher (UCL/GOSH), Professor David Williams (Boston Children’s Hospital) and Professor Robert Wynn (Central Manchester University Hospitals NHS Foundation Trust).
Financial terms:
Latest news:
